The current stock price of TLIS is 4.38 USD. In the past month the price decreased by -50.79%. In the past year, price decreased by -27.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.29 | 219.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.95 | 207.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.35 | 145.84B | ||
| SYK | STRYKER CORP | 27.88 | 140.43B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.49 | 56.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.91 | 49.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.21 | 40.16B | ||
| RMD | RESMED INC | 25.35 | 36.63B | ||
| DXCM | DEXCOM INC | 36.79 | 26.69B | ||
| PODD | INSULET CORP | 64.09 | 20.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.63 | 18.64B |
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
TALIS BIOMEDICAL CORP
1375 West Fulton Market, Suite 700
Chicago ILLINOIS 94025 US
CEO: Brian Coe
Employees: 99
Phone: 16504333000
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
The current stock price of TLIS is 4.38 USD. The price increased by 5.29% in the last trading session.
TLIS does not pay a dividend.
TLIS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
TLIS stock is listed on the Nasdaq exchange.
TALIS BIOMEDICAL CORP (TLIS) has a market capitalization of 7.97M USD. This makes TLIS a Nano Cap stock.
The outstanding short interest for TALIS BIOMEDICAL CORP (TLIS) is 0.25% of its float.
ChartMill assigns a fundamental rating of 3 / 10 to TLIS. No worries on liquidiy or solvency for TLIS as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months TLIS reported a non-GAAP Earnings per Share(EPS) of -31.43. The EPS increased by 42.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.35% | ||
| ROE | -100.93% | ||
| Debt/Equity | 0 |
6 analysts have analysed TLIS and the average price target is 5.1 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 4.38.
For the next year, analysts expect an EPS growth of 27.62% and a revenue growth -100% for TLIS